<Abstract>Background and Objective:Cytokine-induced killer(CIK) cells and autologous dendritic cells-CIK(DCCIK) cells co-cultured with autologous dendritic cells(DCs) and CIK cells are commonly used for immunoth...<Abstract>Background and Objective:Cytokine-induced killer(CIK) cells and autologous dendritic cells-CIK(DCCIK) cells co-cultured with autologous dendritic cells(DCs) and CIK cells are commonly used for immunotherapy recently.We compared the anti-tumor immune response of CIK cells,autologous DC-CIK cells,and semi-allogeneic DC-CIK cells to explore a more effective anti-tumor adoptive immunotherapy approach.Met hods:Peripheral monocytes were isolated from patients with renal carcinoma,lung cancer,or maxillary squamous cell carcinoma and their healthy adult children.Isolated cells were cultured and induced as DCs and CIK cells in vitro.CIK cells from patients were co-cultured with autologous DCs and DCs from their children respectively,generating DC-CIK cells and semi-allogeneic DC-CIK cells.The anti-tumor activities of autologous CIK cells,autologous DC-CIK cells,and semi-allogeneic DC-CIK cells were measured by LDH assay.Intracellular staining was used to test the secretion of cytokines.Flow cytometry was applied for detecting the phonotype changes of these three types of cells.Cell proliferation and cell apoptosis were detected by 5,6carboxyfluorescein diacetate succinimidyl ester(CFSE) and Annexin V/PI respectively.Result s:Compared with autologous CIK cells and DC-CIK cells,semi-allogeneic DC-CIK cells significantly enhanced the anti-tumor activity and IFN-γ secretion,reduced IL-4 secretion,increased the ratio of CD3+CD56+ cells and CD3+CD8+ cells,decreased the number of CD4+CD25+ cells,promoted cell proliferation,and lessened cell apoptosis.Conclusions:Semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than did autologous CIK cells and DC-CIK cells.Our results provided experimental evidence for clinical application of DC-CIK cells.展开更多
AIM: To analyze the correlation between cytokineinduced killer (CIK) cells adoptive immunotherapy and cancer-related death in gastric cancer patients. METHODS: One hundred and fifty-six gastric cancer patients after o...AIM: To analyze the correlation between cytokineinduced killer (CIK) cells adoptive immunotherapy and cancer-related death in gastric cancer patients. METHODS: One hundred and fifty-six gastric cancer patients after operation at the Third Affiliated Hospital of Soochow University were enrolled in this study. Their clinical data including demographic characteristics, operation time, tumor size, pathological type and staging, tumor metastasis, outcome of chemotherapy or CIK cells adoptive immunotherapy, survival time or time of death were collected with a standard structured questionnaire. Kaplan-Meier method was used to estimate the median survival time, and the 2- and 5- year survival rates. Hazard risk (HR) and 95% confidence interval (95% CI) of CIK cells adoptive immunotherapy for gastric cancer were calculated using the two-stage time-dependent covariates Cox model. RESULTS: The survival time of gastric cancer patients was longer after CIK cells adoptive immunotherapy than after chemotherapy (χ 2 = 10.907, P = 0.001). The median survival time of gastric cancer patients was also longer after CIK cells adoptive immunotherapy than after chemotherapy (49 mo vs 27 mo, P < 0.05). The 2- and 5-year survival rates of gastric cancer patients were significantly higher after CIK cells adoptive immunotherapy than after chemotherapy (73.5% vs 52.6%, 40.4% vs 23.9%, P < 0.05). A significant difference was observed in the survival curve for patients who received CIK cells adoptive immunotherapy (0, 1-10, 11-25, and over 25 frequencies) (χ 2 = 14.534, P = 0.002). The frequencies of CIK cells adoptive immunotherapy were significantly related with the decreasing risk of death in gastric cancer patients after adjustment for sex and age of the patients, tumor stage and relapse (HR = 0.54, 95% CI: 0.36-0.80) when the first stage Cox model was used to define the subjects who remained alive beyond 36 mo as survivors. However, no correlation was observed between the frequencies of death in CIK cells adoptive immunotherapy and the 展开更多
Background It remains a challenge to inhibit the local recurrence or distant metastasis of localized or locally advanced renal cell carcinoma （RCC） after surgical resection. We investigated the feasibility, safety a...Background It remains a challenge to inhibit the local recurrence or distant metastasis of localized or locally advanced renal cell carcinoma （RCC） after surgical resection. We investigated the feasibility, safety and efficacy of immunotherapy using autologous tumor lysate （TL）-pulsed dendritic cells （DCs） and cytokine-induced killer （CIK） cells in patients with localized or locally advanced RCC.展开更多
The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available pu...The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years.A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer,presenting potential widespread applications of CIK cells for the future.Furthermore,this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells.However,at present,there are no uniform criteria or large-scale preparations of CIK cells.The overall clinical response is difficult to evaluate because of the use of autologous CIK cells.Based on these observations,several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review.Large-scale,controlled,grouped,and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision.These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.展开更多
基金supported by Poten Biomedical Technology Development Co.,Ltd.
文摘<Abstract>Background and Objective:Cytokine-induced killer(CIK) cells and autologous dendritic cells-CIK(DCCIK) cells co-cultured with autologous dendritic cells(DCs) and CIK cells are commonly used for immunotherapy recently.We compared the anti-tumor immune response of CIK cells,autologous DC-CIK cells,and semi-allogeneic DC-CIK cells to explore a more effective anti-tumor adoptive immunotherapy approach.Met hods:Peripheral monocytes were isolated from patients with renal carcinoma,lung cancer,or maxillary squamous cell carcinoma and their healthy adult children.Isolated cells were cultured and induced as DCs and CIK cells in vitro.CIK cells from patients were co-cultured with autologous DCs and DCs from their children respectively,generating DC-CIK cells and semi-allogeneic DC-CIK cells.The anti-tumor activities of autologous CIK cells,autologous DC-CIK cells,and semi-allogeneic DC-CIK cells were measured by LDH assay.Intracellular staining was used to test the secretion of cytokines.Flow cytometry was applied for detecting the phonotype changes of these three types of cells.Cell proliferation and cell apoptosis were detected by 5,6carboxyfluorescein diacetate succinimidyl ester(CFSE) and Annexin V/PI respectively.Result s:Compared with autologous CIK cells and DC-CIK cells,semi-allogeneic DC-CIK cells significantly enhanced the anti-tumor activity and IFN-γ secretion,reduced IL-4 secretion,increased the ratio of CD3+CD56+ cells and CD3+CD8+ cells,decreased the number of CD4+CD25+ cells,promoted cell proliferation,and lessened cell apoptosis.Conclusions:Semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than did autologous CIK cells and DC-CIK cells.Our results provided experimental evidence for clinical application of DC-CIK cells.
基金Supported by The National Natural Science Foundation of China, No. 30872176, 30950022 and 30972703grants of Jiangsu Province and Soochow University Medical Development Foundation, No. EE126765
文摘AIM: To analyze the correlation between cytokineinduced killer (CIK) cells adoptive immunotherapy and cancer-related death in gastric cancer patients. METHODS: One hundred and fifty-six gastric cancer patients after operation at the Third Affiliated Hospital of Soochow University were enrolled in this study. Their clinical data including demographic characteristics, operation time, tumor size, pathological type and staging, tumor metastasis, outcome of chemotherapy or CIK cells adoptive immunotherapy, survival time or time of death were collected with a standard structured questionnaire. Kaplan-Meier method was used to estimate the median survival time, and the 2- and 5- year survival rates. Hazard risk (HR) and 95% confidence interval (95% CI) of CIK cells adoptive immunotherapy for gastric cancer were calculated using the two-stage time-dependent covariates Cox model. RESULTS: The survival time of gastric cancer patients was longer after CIK cells adoptive immunotherapy than after chemotherapy (χ 2 = 10.907, P = 0.001). The median survival time of gastric cancer patients was also longer after CIK cells adoptive immunotherapy than after chemotherapy (49 mo vs 27 mo, P < 0.05). The 2- and 5-year survival rates of gastric cancer patients were significantly higher after CIK cells adoptive immunotherapy than after chemotherapy (73.5% vs 52.6%, 40.4% vs 23.9%, P < 0.05). A significant difference was observed in the survival curve for patients who received CIK cells adoptive immunotherapy (0, 1-10, 11-25, and over 25 frequencies) (χ 2 = 14.534, P = 0.002). The frequencies of CIK cells adoptive immunotherapy were significantly related with the decreasing risk of death in gastric cancer patients after adjustment for sex and age of the patients, tumor stage and relapse (HR = 0.54, 95% CI: 0.36-0.80) when the first stage Cox model was used to define the subjects who remained alive beyond 36 mo as survivors. However, no correlation was observed between the frequencies of death in CIK cells adoptive immunotherapy and the
基金This study was supported by grants from the National Natural Science Foundation of China （No. 30772178）, Medical Research Fund of Science and Technology of Guangdong （No. B2007062）, Research Fund for the Doctoral Program of Higher Education of China （No. 20060558032）, Natural Science Foundation of Guangdong Province （No. 7117362） and the Program of 5010 of Sun Yat-sen Universitty （No. 2007028）. Conflicts of interest： none.
文摘Background It remains a challenge to inhibit the local recurrence or distant metastasis of localized or locally advanced renal cell carcinoma （RCC） after surgical resection. We investigated the feasibility, safety and efficacy of immunotherapy using autologous tumor lysate （TL）-pulsed dendritic cells （DCs） and cytokine-induced killer （CIK） cells in patients with localized or locally advanced RCC.
基金supported by the grants from the National Natural Science Foundation of China(31270820,81230061 and 81402566)partially supported by a grant from the 2013BA101B00
文摘The accumulation of basic researches and clinical studies related to cytokine-induced killer(CIK) cells has confirmed their safety and feasibility in treating malignant diseases.This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years.A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer,presenting potential widespread applications of CIK cells for the future.Furthermore,this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells.However,at present,there are no uniform criteria or large-scale preparations of CIK cells.The overall clinical response is difficult to evaluate because of the use of autologous CIK cells.Based on these observations,several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review.Large-scale,controlled,grouped,and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision.These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.
